The Importance of Zoster Prevention Vaccines

  • C. Peter N. WatsonEmail author


Herpes zoster is the commonest neurological disease [11] and is likely to increase as the population ages. There are many complications of herpes zoster of which severe postherpetic neuralgia is the most common and much feared. Other related consequences are blindness and facial scarring with ophthalmic zoster, facial paralysis (Ramsay Hunt syndrome), meningitis, encephalitis, myelitis, and the potential for an increased vascular risk of granulomatous angiitis, stroke, and myocardial infarction. Postherpetic neuralgia specifically may be compared with other end-stage disorders in which damage to an organ occurs and that structure is unable or not fully able to repair itself and respond to treatment. Several categories of evidence support this view and argue for prevention of herpes zoster by vaccination. These data are clinical, pathological, therapeutic, preventative, and epidemiological.


  1. 1.
    Beutner KR, Friedman DJ, Porszpaniak D, Anderson PL, Wood MJ (1995) Valacyclovir compared acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39:1546–1533CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bowsher D (1996) Postherpetic neuralgia and its treatment: a retrospective survey of 191 patients. J Pain Symp Manage 12:327–331CrossRefGoogle Scholar
  3. 3.
    Brisson M, Pellissier JM, Camden S et al (2008) The potential cost effectiveness of the vaccine against herpes zoster and post herpetic neuralgia. Hum Vaccin 493(3):238–245CrossRefGoogle Scholar
  4. 4.
    Burgoon CP, Burgoon JS, Haldridge GD (1957) The natural history of herpes zoster. JAMA 164:265–269CrossRefGoogle Scholar
  5. 5.
    Chen N, Li Q, Yang T et al (2014) Antiviral therapy for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev (2):CD006866Google Scholar
  6. 6.
    De Moragas JM, Kierland RR (1957) The outcome of patients with herpes zoster. Arch Dermatol 75:193–196CrossRefGoogle Scholar
  7. 7.
    Dworkin RH, Corbin AE, Young JP et al (2003) Pregabalin for postherpetic neuralgia: a randomized placebo-controlled study. Neurology 60(8):1174–1283CrossRefGoogle Scholar
  8. 8.
    Hope-Simpson RE (1975) Postherpetic neuralgia. J R Coll Gen Pract 25:571–575PubMedPubMedCentralGoogle Scholar
  9. 9.
    Insinga DRP, Itzler RF, Pellissier JM et al (2005) The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20(8):748–653CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kishore-Kumar R, Max MB, Schafer SC et al (1990) Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 47:305–312CrossRefPubMedGoogle Scholar
  11. 11.
    Kurtzke JF (1984) Neuroepidemiology. Ann Neurol 16:265–277CrossRefPubMedGoogle Scholar
  12. 12.
    Lal H, Cunningham AL, Godeaux O et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087–2296CrossRefGoogle Scholar
  13. 13.
    Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely R (1988) Amitriptyline but not lorazepam relieves postherpetic neuralgia. Neurology 38:1427–1432CrossRefPubMedGoogle Scholar
  14. 14.
    Oxman MN, Levin M, Johnson GR et al (2005) A vaccine to prevent herpes zosterand postherpetic neuralgia in older adults. N Eng J Med 352:2271–2284. 13Google Scholar
  15. 15.
    Ragozzino MW, Melton IJ, Kurland IT et al (1982) Population based study of herpes zoster and its sequelae. Medicine 21:310–316CrossRefGoogle Scholar
  16. 16.
    Rowbotham MC, Harden N, Stacey B et al (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280(21):1837–1842CrossRefGoogle Scholar
  17. 17.
    Tyring S, Barbarash RA, Nahlek JE et al (1995) Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia. Ann Intern Med 123:89–96CrossRefPubMedGoogle Scholar
  18. 18.
    Watson CPN, Evans RJ, Reed K, Merskey H, Goldsmith I, Warsh J (1982) Amitriptyline versus placebo in postherpetic neuralgia. Neurology 32:671–673CrossRefPubMedGoogle Scholar
  19. 19.
    Watson CPN, Morshead C, Van der Kooy D, Deck J, Evans RJ (1988a) Postherpetic neuralgia: post-mortem analysis of a case. Pain 34:129–138CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Watson CPN, Evans RJ, Watt VR, Birkett N (1988b) Postherpetic neuralgia: 208 cases. Pain 35:289–298CrossRefPubMedGoogle Scholar
  21. 21.
    Watson CPN, Deck JH, Morshead C, Van der Kooy D, Evans RJ (1991a) Postherpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 44:105–117CrossRefGoogle Scholar
  22. 22.
    Watson CPN, Watt RR, Chipman M, Birkett N, Evans RJ (1991b) The prognosis with postherpetic neuralgia. Pain 45:195–199CrossRefGoogle Scholar
  23. 23.
    Watson CPN, Chipman M, Reed K, Evans RJ, Birkett N (1992) Amitriptyline versus maprotiline in postherpetic neuralgia; a randomized double-blind, crossover trial. Pain 48:29–36CrossRefPubMedGoogle Scholar
  24. 24.
    Watson CPN (1995) The treatment of postherpetic neuralgia. Neurology 45:58–59CrossRefGoogle Scholar
  25. 25.
    Watson CPN, Babul N (1998) Oxycodone relives neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50:1837–1841CrossRefGoogle Scholar
  26. 26.
    Watson CPN, Chipman M, Reed K (1998) Amitriptyline versus nortriptyline in postherpetic neuralgia. Neurology 51:1166–1171CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of MedicineUniversity of TorontoTorontoCanada

Personalised recommendations